Placental Transfer of Rilpivirine in an Ex Vivo Human Cotyledon Perfusion Model | Zendy

Laurent Mandelbrot | Zendy; Dominique Duro | Zendy; Émilie Belissa | Zendy; Gilles Peytavin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Placental Transfer of Rilpivirine in an Ex Vivo Human Cotyledon Perfusion Model

Author(s) -

Laurent Mandelbrot,

Dominique Duro,

Émilie Belissa,

Gilles Peytavin

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00075-15

Subject(s) - rilpivirine , ex vivo , fetus , placenta , pharmacokinetics , perfusion , pharmacology , in vivo , medicine , pregnancy , virology , biology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , genetics , microbiology and biotechnology

Placental transfers of the HIV nonnucleoside reverse transcriptase inhibitor rilpivirine were investigated in 8 term human cotyledons perfused with rilpivirine (400 ng/ml) in the maternal-to-fetal direction. The mean fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 15 to 90 min) was 26% ± 8% (mean ± standard deviation), and the clearance index (rilpivirine FTR/antipyrine FTR) was 61% ± 20%. This shows that rilpivirine crosses the placenta at a relatively high rate, suggesting that the fetus is exposed to the compound during treatment of the mother.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research